Hematology-Oncology
High Efficacy and Safety of Glofitamab Plus Polatuzumab-R-CHP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Multicenter Study
A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.
